Samjin Pharm (KO:005500) — Market Cap & Net Worth
Market Cap & Net Worth: Samjin Pharm (005500)
Samjin Pharm (KO:005500) has a market capitalization of $152.76 Million (₩225.42 Billion) as of September 16, 2026. Listed on the KO stock exchange, this Korea-based company holds position #17663 globally and #728 in its home market, demonstrating a -2.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Samjin Pharm's stock price ₩18390.00 by its total outstanding shares 12257775 (12.26 Million). Also see total assets of Samjin Pharm for a full breakdown of the balance sheet.
Samjin Pharm Market Cap History: 2015 to 2026
Samjin Pharm's market capitalization history from 2015 to 2026. Data shows change from $160.47 Million to $152.76 Million (-0.75% CAGR). Also see Samjin Pharm cash conversion from operations for how efficiently the company converts equity into cash flow.
Samjin Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Samjin Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Samjin Pharm for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
Samjin Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Samjin Pharm's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $160.47 Million | $216.51 Billion | $27.04 Billion | 0.00x | 0.01x |
| 2016 | $244.77 Million | $239.31 Billion | $30.17 Billion | 0.00x | 0.01x |
| 2017 | $258.30 Million | $245.27 Billion | $35.80 Billion | 0.00x | 0.01x |
| 2018 | $295.23 Million | $260.02 Billion | $25.53 Billion | 0.00x | 0.01x |
| 2019 | $189.34 Million | $241.93 Billion | $11.88 Billion | 0.00x | 0.02x |
| 2020 | $212.90 Million | $235.16 Billion | $27.88 Billion | 0.00x | 0.01x |
| 2021 | $211.80 Million | $250.07 Billion | $28.40 Billion | 0.00x | 0.01x |
| 2022 | $213.07 Million | $274.03 Billion | $21.89 Billion | 0.00x | 0.01x |
| 2023 | $179.43 Million | $292.13 Billion | $18.91 Billion | 0.00x | 0.01x |
| 2024 | $150.11 Million | $308.35 Billion | $39.23 Billion | 0.00x | 0.00x |
Competitor Companies of 005500 by Market Capitalization
Companies near Samjin Pharm in the global market cap rankings as of September 16, 2026. Review how tangible is Samjin Pharm's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Samjin Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Samjin Pharm Historical Marketcap From 2015 to 2026
Between 2015 and today, Samjin Pharm's market cap moved from $160.47 Million to $ 152.76 Million, with a yearly change of -0.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩152.76 Million | -6.89% |
| 2025 | ₩164.06 Million | +9.30% |
| 2024 | ₩150.11 Million | -16.34% |
| 2023 | ₩179.43 Million | -15.79% |
| 2022 | ₩213.07 Million | +0.60% |
| 2021 | ₩211.80 Million | -0.52% |
| 2020 | ₩212.90 Million | +12.44% |
| 2019 | ₩189.34 Million | -35.87% |
| 2018 | ₩295.23 Million | +14.30% |
| 2017 | ₩258.30 Million | +5.53% |
| 2016 | ₩244.77 Million | +52.53% |
| 2015 | ₩160.47 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Samjin Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $152.76 Million USD |
| MoneyControl | $152.76 Million USD |
| MarketWatch | $152.76 Million USD |
| marketcap.company | $152.76 Million USD |
| Reuters | $152.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Samjin Pharm
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also… Read more